Business
Sierra Oncology has reported its 2018 Results
Sierra Oncology has reported its 2018 Results.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 4733R Sareum Holdings PLC 28 February 2019 \n\n\n\n\n(AIM: SAR)\n\n\n28 February 2019\n\n\n\n \nSareum Holdings plc\n(\"Sareum\" or \"the Company\")\n \nLicence holder for SRA737, Sierra Oncology, has reported its 2018 Year End Results\nSareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, notes that Sierra Oncology (\"Sierra\"), the licence holder advancing clinical cancer candidate SRA737, has announced its 2018 full year results in which it provides a review of progress made on the development of SRA737.\n \nIn the statement, Sierra CEO Nick Glover commented \"We have enrolled a substantial number of patients into the two ongoing trials for our oral Chk1 inhibitor, SRA737, and remain on track to report clinical data from these studies in the first half of 2019.\"\n \nThe full announcement can be found by clicking here: \n \nSareum also notes that it will publish its interim results for the six months to end December 2018 on 4 March 2019.\n \n \nFor further information, please contact: \n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser)\n\n\n\n\nChris Fielding / James Sinclair-Ford\n\n\n020 7220 1666\n\n\n\n\nHybridan LLP (Nominated Broker)\n\n\n \n\n\n\n\nClaire Noyce\n\n\n020 3764 2341\n\n\n\n\nCitigate Dewe Rogerson (Media enquiries)\n\n\n \n\n\n\n\nShabnam Bashir/ Mark Swallow/ David Dible\n\n\n020 7638 9571\n\n\n\nNotes for editors: \nSareum is a specialist drug development company delivering targeted small molecule therapeutics, to improve the treatment of cancer and autoimmune disease. The Company generates value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.\nSareum's leading clinical-stage programme, SRA737, a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology, is in Phase 2 clinical trials targeting ovarian and other advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in combination with other oncology and immune-oncology drugs in genetically defined patients.\nSareum is a...